ERBB2 and breast cancer: Novel HER2-targeting agents have, however, improved outcomes in patients with HER2-positive breast cancer to a comparable level to those in patients with HER2-negative disease [3], if not greater relative to certain subtypes (for example, basal-like breast cancers).